Anxiolytics

Name: Anxiolytics
Brand: Birkhauser Verlag AG
SKU: 9783764360320
Price: 581.45 RON
Availability: InStock

Autor: Mike Briley, David Nutt

Limbă:

Legare: Copertă tare

Editura: Birkhauser Verlag AG

Disponibilitate: În depozitul extern în cantități mici

Expediem în 13-18 zile

581.45 lei

For over thirty years the benzodiazepines monopolised not only the anxiolytic market but also clinic...

Informații despre carte

Autor

Mike Briley, David Nutt

Limbă

engleză

Legare

Carte - Copertă tare

Publicat

2000

Pagini

181

EAN

9783764360320

ISBN

3764360321

Enbook ID

05289180

Editura

Birkhauser Verlag AG

Greutate

1000

Dimensiuni

155 x 235 x 20

Descriere completă

For over thirty years the benzodiazepines monopolised not only the anxiolytic market but also clinical and animal research in anxiety. Indeed many animal tests developed since the 1960s have been optimised for the benzodiazepines and some programmes have even screened candidates as potential anxiolytics on their benzodiazepine-like side-effects rather than their anxiolytic activity. With the realisation of the drawbacks of the benzodiazepines, namely their potential for tolerance and dependency, there has been a renewed interest in alternative anxiolytics both from existing drugs such as the tricyclic and monoamine oxidase antidepressants and from newer agents such as buspirone. In addition anxiety is no longer considered to be a unique entity but rather an umbrella term for a series of specific anxiety disorders such as panic disorder without or with agoraphobia, generalised anxiety disorder (GAD), specific phobias, social phobias and post-traumatic stress disorder (PTSD). These new clinical categories have opened another dimension in the therapy of anxiety requiring the optimisation of treatments for different syndromes. This book is a critical review of today's anxiolytics and those that may become the anxiolytics of tomorrow. What is clear is that currently there are few clinically satisfactory alternatives to the benzodiazepines for the treatment of acute anxiety. For chronic anxiety, it is generally agreed that benzodi azepines are not the treatment of first choice. The tricyclic and monoamine oxidase antidepressants, the serotonin reuptake inhibitors and buspirone offer better solutions for chronic anxiety but they are still far from being ideal.

S-ar putea să te intereseze

Clienții care au cumpărat această carte au mai cumpărat și

Cele mai căutate

Categories

Authors

Publishers

Produse

Produse

Cele mai căutate

Categories

Authors

Publishers

Produse

Produse

Anxiolytics

Informații despre carte

Descriere completă

S-ar putea să te intereseze

Clienții care au cumpărat această carte au mai cumpărat și